1. Home
  2. MGNX vs AUBN Comparison

MGNX vs AUBN Comparison

Compare MGNX & AUBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • AUBN
  • Stock Information
  • Founded
  • MGNX 2000
  • AUBN 1907
  • Country
  • MGNX United States
  • AUBN United States
  • Employees
  • MGNX N/A
  • AUBN N/A
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • AUBN Major Banks
  • Sector
  • MGNX Health Care
  • AUBN Finance
  • Exchange
  • MGNX Nasdaq
  • AUBN Nasdaq
  • Market Cap
  • MGNX 97.2M
  • AUBN 68.1M
  • IPO Year
  • MGNX 2013
  • AUBN 1995
  • Fundamental
  • Price
  • MGNX $1.36
  • AUBN $20.96
  • Analyst Decision
  • MGNX Hold
  • AUBN
  • Analyst Count
  • MGNX 9
  • AUBN 0
  • Target Price
  • MGNX $5.33
  • AUBN N/A
  • AVG Volume (30 Days)
  • MGNX 378.7K
  • AUBN 1.1K
  • Earning Date
  • MGNX 05-13-2025
  • AUBN 07-22-2025
  • Dividend Yield
  • MGNX N/A
  • AUBN 5.15%
  • EPS Growth
  • MGNX N/A
  • AUBN 717.98
  • EPS
  • MGNX N/A
  • AUBN 1.88
  • Revenue
  • MGNX $154,050,000.00
  • AUBN $31,155,000.00
  • Revenue This Year
  • MGNX N/A
  • AUBN N/A
  • Revenue Next Year
  • MGNX $45.52
  • AUBN N/A
  • P/E Ratio
  • MGNX N/A
  • AUBN $11.17
  • Revenue Growth
  • MGNX 255.31
  • AUBN 38.25
  • 52 Week Low
  • MGNX $0.99
  • AUBN $16.48
  • 52 Week High
  • MGNX $5.77
  • AUBN $25.40
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 39.88
  • AUBN 57.83
  • Support Level
  • MGNX $1.44
  • AUBN $19.91
  • Resistance Level
  • MGNX $1.58
  • AUBN $21.00
  • Average True Range (ATR)
  • MGNX 0.11
  • AUBN 0.27
  • MACD
  • MGNX -0.02
  • AUBN 0.07
  • Stochastic Oscillator
  • MGNX 17.65
  • AUBN 96.33

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About AUBN Auburn National Bancorporation Inc.

Auburn National Bancorp Inc operates as a bank holding company, which offers checking, savings, transaction deposit accounts and certificates of deposit, and is an active residential mortgage lender in its primary service area. The Bank's primary service area includes the cities of Auburn and Opelika, Alabama and nearby surrounding areas in East Alabama, predominantly in Lee County. The Bank also offers commercial, financial, agricultural, real estate construction and consumer loan products and other financial services. The Bank also provides automated teller machine (ATM) services in East Alabama and operates ATM machines. The Bank offers Visa Checkcards, which are debit cards. The Bank offers online banking, bill payment and other electronic banking services through its Internet website.

Share on Social Networks: